Form 4 for PCRX Pacira BioSciences, Inc.
Accepted 2026-02-13 00:00:00 ET · period of report 2026-02-11 · accession 0001628280-26-008077 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-02-13 | 2026-02-11 | PCRX | Teehan Brendan | Chief Commercial Off | A - Grant | $0.00 | +51.7K | 100.9K | +105% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2026-02-11 | A | A | 51,714 | $0.00 | 100,934.27 | D | — | — | (F1) Represents restricted stock units that vest in four equal annual installments beginning on February 15, 2027, provided that the reporting person remains in continuous service with the issuer as of each vesting date. Each restricted stock unit represents the contingent right to receive one share of the issuer's common stock. |